$138.88
0.18% yesterday
NYSE, Dec 24, 07:00 pm CET
ISIN
US66987V1098
Symbol
NVS

Novartis ADR Stock price

$138.88
+12.34 9.75% 1M
+20.05 16.87% 6M
+41.57 42.72% YTD
+40.53 41.21% 1Y
+52.86 61.44% 3Y
+55.05 65.67% 5Y
+57.02 69.66% 10Y
+89.88 183.43% 20Y
NYSE, Closing price Wed, Dec 24 2025
-0.25 0.18%
ISIN
US66987V1098
Symbol
NVS
Industry

New AI Insights on Novartis ADR Insights AI Insights on Novartis ADR

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$265.7b
Enterprise Value
$288.0b
Net debt
$22.3b
Cash
$9.7b
Shares outstanding
1.9b
Valuation (TTM | estimate)
P/E
18.7 | 15.2
P/S
4.7 | 4.7
EV/Sales
5.1 | 5.1
EV/FCF
16.9
P/B
6.0
Dividends
DPS
$3.99
Yield 1Y | 5Y
2.9% | 3.6%
Growth 1Y | 5Y
6.8% | 6.4%
Payout 1Y | 3Y
63.7% | 63.3%
Increased
6 Years
Financials (TTM | estimate)
Revenue
$56.0b | $56.6b
EBITDA
$18.9b | $23.6b
EBIT
$18.6b | $21.3b
Net Income
$14.4b | $17.5b
Free Cash Flow
$17.1b
Growth (TTM | estimate)
Revenue
12.2% | 9.4%
EBITDA
22.7% | 42.8%
EBIT
21.6% | 30.6%
Net Income
-18.2% | 46.6%
Free Cash Flow
29.7%
Margin (TTM | estimate)
Gross
76.1%
EBITDA
33.8% | 41.7%
EBIT
33.1%
Net
25.7% | 30.9%
Free Cash Flow
30.5%
Financial Health
Equity Ratio
43.1%
Return on Equity
27.1%
ROCE
24.6%
ROIC
22.2%
Debt/Equity
0.7
More
EPS
$7.4
FCF per Share
$8.9
Short interest
0.3%
Employees
76k
Rev per Employee
$680.0k
Show more

Is Novartis ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Novartis ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Novartis ADR forecast:

14x Buy
45%
13x Hold
42%
4x Sell
13%

Analyst Opinions

31 Analysts have issued a Novartis ADR forecast:

Buy
45%
Hold
42%
Sell
13%

Financial data from Novartis ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
56,024 56,024
12% 12%
100%
- Direct Costs 13,392 13,392
7% 7%
24%
42,632 42,632
14% 14%
76%
- Selling and Administrative Expenses 13,303 13,303
6% 6%
24%
- Research and Development Expense 10,034 10,034
11% 11%
18%
18,939 18,939
23% 23%
34%
- Depreciation and Amortization 388 388
112% 112%
1%
EBIT (Operating Income) EBIT 18,551 18,551
22% 22%
33%
Net Profit 14,393 14,393
18% 18%
26%

In millions USD.

Don't miss a Thing! We will send you all news about Novartis ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis ADR Stock News

Neutral
The Motley Fool
3 days ago
Novartis has proved that it can navigate headwinds such as patent cliffs and a slow economy. Shopify's long-term ambitions are off to a great start, given its large addressable market and economic moat.
Neutral
WSJ
6 days ago
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Positive
The Guardian
6 days ago
Officials pledge ‘massive savings' as companies agree to offer drugs at prices paid in other wealthy countries
More Novartis ADR News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 75,883
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today